MedTrace Logo

Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery

NCT02819908 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-03-09

Study results available
· View outcomes & findings →

Summary

To compare the relative effectiveness of the Imprimis Dropless™ (TriMoxiVanc) intraocular solution with the Less Drops™ topical formulation of PredMoxiKeterolac (given for the first week post op) followed by PredKeterolac (given for weeks 2 to 4 after surgery).

The hypothesis is that the "dropless" regimen will be non-inferior to the "less drops" regimen in terms of post-operative IOP changes, post-operative healing, and visual quality.

Conditions

  • Intraocular Lens Associated Postoperative Inflammation

Interventions

DRUG

Imprimis Dropless

Tri-Moxi-Vanc transzonular intravitreal injection

DRUG

Imprimis Less Drops

Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively

Sponsors & Collaborators

  • Eye Center of North Florida

    lead OTHER

Principal Investigators

  • Bret L Fisher, MD · Eye Center of North Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02819908 on ClinicalTrials.gov